Skip to main content
. 2016 Jul 26;13(8):638–645. doi: 10.7150/ijms.16187

Table 1.

Clinical and demographic details of patients with VAP, non-VAP and healthy control subjects.

Characteristics VAP non-VAP Control
(n=30) (n=12) (n=30)
Age (yrs) 64.30± 3.19 52.67± 5.80 35.73 ± 2.20a,b
Male gender 25 (83.3%) 8 (66.7%) 27 (90.0%)
Inflammation markers at study enrollment
WBC (/mm3) 16476.67 ± 1158.26 8350.00 ± 953.73a 7049.67 ± 281.37a
Neutrophils (/mm3) 13285.40 ± 1088.20 5264.56 ± 898.17a 4058.63 ± 208.82a
CRP (ng/dl) 16.15 ± 1.69 - -
Reason for mechanical ventilation
Surgical 11 (36.7%) 10 (83.3%)a
Pneumonia 2 (6.7%) 0
Pleural effusion / Pulmonary edema 4 (13.3%) 0
COPD with Acute Exacerbation 1 (3.3%) 0
Cardiac arrest 2 (6.7%) 0
Renal failure 1 (3.3%) 0
Neurologic failure 6 (20.0%) 1 (8.3%)
Cardiovascular 0 1 (8.3%)
Hypovomemic shock 4 (13.3%) 0
Sepsis 4 (13.3%) 0
Coexisting illnesses
Pulmonary 4 (13.3%) 1 (8.3%)
Cardiac 8 (26.7%) 3 (25.0%)
Liver 3 (10.0%) 0
Renal 4 (13.3%) 0
Cancer 10 (33.3%) 7 (58.3%)
Cerebral vascular accident 4 (13.3%) 3 (25.0%)
Scores at study enrollment
CPIS 6.40 ± 0.27 1.58 ± 0.26a

WBC, white blood cell; CRP, C-reactive protein; COPD, chronic obstructive pulmonary disease; CPIS, Clinical Pulmonary Infection Score; VAP, ventilator-associated pneumonia; discrete variables are expressed as counts (%) and continuous variables as mean ± SE. a p value < 0.05 was considered significant in patients of VAP v.s non-VAP or health control subjects, b p value < 0.05 was considered significant in patients of non-VAP v.s healthy control subjects.